Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone
McDougle C, Scahill L, McCracken J, Aman M, Tierney E, Arnold L, Freeman B, Martin A, McGough J, Cronin P, Posey D, Riddle M, Ritz L, Swiezy N, Vitiello B, Volkmar F, Votolato N, Walson P. Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 201-224. PMID: 10674197, DOI: 10.1016/s1056-4993(18)30142-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsAutistic DisorderBrainChildClinical Trials as TopicHumansReceptors, DopamineReceptors, SerotoninRisperidoneConceptsOpen-label trialDA neuronal systemsSafety of risperidoneStudy of RisperidonePlacebo-controlled studyUse of risperidoneExtrapyramidal side effectsTarget of pharmacotherapyTreatment of childrenImpaired social behaviorLong-term effectivenessPreclinical evidenceReceptor blockadeTypical antipsychoticsControlled StudyFirst drugPathophysiology of autismLower riskShort-term benefitsSide effectsRisperidonePotent effectsSymptoms of autismNeuronal systemsEnhanced efficacyPharmacotherapy of Early-Onset Depression Update and New Directions
Martin A, Kaufman J, Charney D. Pharmacotherapy of Early-Onset Depression Update and New Directions. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 135-157. PMID: 10674194, DOI: 10.1016/s1056-4993(18)30139-1.Peer-Reviewed Original ResearchConceptsEarly-onset depressionDepressive disorderSafety dataLong-term exposureBrain-derived neurotrophic factor levelsLong-term safety dataEarly-onset depressive disordersAvailable antidepressant agentsRigid treatment guidelinesUseful treatment interventionsNeurotrophic factor levelsLong-term followShort-term efficacyShort-term efficacy dataAtrophic brain changesHigh recurrence ratePsychopharmacology Algorithm ProjectRoutine clinical practiceAlternative treatment strategiesYears of ageShort-term trialsPaucity of dataRisk-benefit analysisLong-term useAntidepressant medication